The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016
Open accessAbstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection provide recommendations for prostate cancer screening in healthy men who have elected to participate in an early detection program. The NCCN Guidelines focus on minimizing unnecessary procedures and limiting the detection of indolent disease. These NCCN Guidelines Insights summarize the NCCN Prostate Cancer Early Detection Panel's most significant discussions for the 2016 guideline update, which included issues surrounding screening in high-risk populations (ie, African Americans, BRCA1/2 mutation carriers), approaches to refine patient selection for initial and repeat biopsies, and approaches to improve biopsy specificity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Self-citationRisks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Määttänen, L., Lilja, H., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60525-0 · Cited by 1,566
Cancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Siddiqui, M. M., Rais-Bahrami, S., Turkbey, B., George, A. K., Rothwax, J., Shakir, N., Okoro, C., Raskolnikov, D., Parnes, H. L., Linehan, W. M., et al. (2015) · JAMA · doi:10.1001/jama.2014.17942 · Cited by 1,505
Prostate-Cancer Mortality at 11 Years of Follow-up
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113135 · Cited by 1,245
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Isaacs, C., Kvale, P. A., Reding, D. J., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr500 · Cited by 1,121
Self-citationCastro, E., Goh, C., Olmos, D., Saunders, E., Leongamornlert, D., Tymrakiewicz, M., Mahmud, N., Dadaev, T., Govindasami, K., Guy, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1882 · Cited by 850
Mendelian inheritance of familial prostate cancer.
Carter, B. S., Beaty, T. H., Steinberg, G. D., Childs, B., & Walsh, P. C. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3367 · Cited by 781
Schoots, I. G., Roobol, M. J., Nieboer, D., Bangma, C. H., Steyerberg, E. W., & Hunink, M. G. M. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.037 · Cited by 687
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian
Mersch, J., Jackson, M. A., Park, M., Nebgen, D., Peterson, S. K., Singletary, C., Arun, B. K., & Litton, J. K. (2015) · Cancer · doi:10.1002/cncr.29041 · Cited by 511
Pokorny, M. R., de Rooij, M., Duncan, E., Schröder, F. H., Parkinson, R., Barentsz, J. O., & Thompson, L. C. (2014) · European Urology · doi:10.1016/j.eururo.2014.03.002 · Cited by 503
Catalona, W. J., Partin, A. W., Sanda, M. G., Wei, J. T., Klee, G. G., Bangma, C. H., Slawin, K. M., Marks, L. S., Loeb, S., Broyles, D. L., et al. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.12.032 · Cited by 502
Self-citationCancer risks in BRCA2 families: estimates for sites other than breast and ovary
van Asperen, C. J., Brohet, R. M., Meijers-Heijboer, E. J., Hoogerbrugge, N., Verhoef, S., Vasen, H. F. A., Ausems, M. G. E. M., Menko, F. H., Gomez Garcia, E. B., Klijn, J. G. M., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.028829 · Cited by 420
Parekh, D. J., Punnen, S., Sjoberg, D. D., Asroff, S. W., Bailen, J. L., Cochran, J. S., Concepcion, R., David, R. D., Deck, K. B., Dumbadze, I., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.021 · Cited by 414
Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature
Liede, A., Karlan, B. Y., & Narod, S. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.055 · Cited by 407
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations
Moran, A., O’Hara, C., Khan, S., Shack, L., Woodward, E., Maher, E. R., Lalloo, F., & Evans, D. G. R. (2012) · Familial Cancer · doi:10.1007/s10689-011-9506-2 · Cited by 307
Germline BRCA1 mutations increase prostate cancer risk
Collaborators, T. U., Leongamornlert, D., Mahmud, N., Tymrakiewicz, M., Saunders, E., Dadaev, T., Castro, E., Goh, C., Govindasami, K., Guy, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.146 · Cited by 302
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
Gallagher, D. J., Gaudet, M. M., Pal, P., Kirchhoff, T., Balistreri, L., Vora, K., Bhatia, J., Stadler, Z., Fine, S. W., Reuter, V., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2871 · Cited by 301
Powell, I. J., Bock, C. H., Ruterbusch, J. J., & Sakr, W. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.01.015 · Cited by 292
Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
Wei, J. T., Feng, Z., Partin, A. W., Brown, E., Thompson, I., Sokoll, L., Chan, D. W., Lotan, Y., Kibel, A. S., Busby, J. E., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.8505 · Cited by 274
Bancroft, E. K., Page, E. C., Castro, E., Lilja, H., Vickers, A., Sjoberg, D., Assel, M., Foster, C. S., Mitchell, G., Drew, K., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.01.003 · Cited by 254
Self-citationVickers, A., Cronin, A., Roobol, M., Savage, C., Peltola, M., Pettersson, K., Scardino, P. T., Schröder, F., & Lilja, H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1968 · Cited by 235
Self-citationProstate Cancer Progression and Survival in BRCA2 Mutation Carriers
Tryggvadottir, L., Vidarsdottir, L., Thorgeirsson, T., Jonasson, J. G., Olafsdottir, E. J., Olafsdottir, G. H., Rafnar, T., Thorlacius, S., Jonsson, E., Eyfjord, J. E., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm005 · Cited by 231
Hereditary Prostate Cancer: Clinical Aspects
Bratt, O. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64541-7 · Cited by 229
Stewart, G. D., Van Neste, L., Delvenne, P., Delrée, P., Delga, A., McNeill, S. A., O'Donnell, M., Clark, J., Van Criekinge, W., Bigley, J., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2012.08.219 · Cited by 226
Partin, A. W., Van Neste, L., Klein, E. A., Marks, L. S., Gee, J. R., Troyer, D. A., Rieger-Christ, K., Jones, J. S., Magi-Galluzzi, C., Mangold, L. A., et al. (2014) · Journal of Urology · doi:10.1016/j.juro.2014.04.013 · Cited by 226
Self-citationKuru, T. H., Roethke, M. C., Seidenader, J., Simpfendörfer, T., Boxler, S., Alammar, K., Rieker, P., Popeneciu, V. I., Roth, W., Pahernik, S., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.04.043 · Cited by 188
Rastinehad, A. R., Turkbey, B., Salami, S. S., Yaskiv, O., George, A. K., Fakhoury, M., Beecher, K., Vira, M. A., Kavoussi, L. R., Siegel, D. N., et al. (2014) · Journal of Urology · doi:10.1016/j.juro.2013.12.007 · Cited by 188
Bryant, R. J., Sjoberg, D. D., Vickers, A. J., Robinson, M. C., Kumar, R., Marsden, L., Davis, M., Scardino, P. T., Donovan, J., Neal, D. E., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv095 · Cited by 184
Self-citationProstate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
Collaborators, T. I. A. E., Mitra, A., Fisher, C., Foster, C. S., Jameson, C., Barbachanno, Y., Bartlett, J., Bancroft, E., Doherty, R., Kote-Jarai, Z., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604132 · Cited by 173
BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews
Kirchhoff, T., Kauff, N. D., Mitra, N., Nafa, K., Huang, H., Palmer, C., Gulati, T., Wadsworth, E., Donat, S., Robson, M. E., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0604 · Cited by 165
Rapid progression of prostate cancer in men with a BRCA2 mutation
the Hereditary Breast Cancer Study Group, Narod, S. A., Neuhausen, S., Vichodez, G., Armel, S., Lynch, H. T., Ghadirian, P., Cummings, S., Olopade, O., Stoppa-Lyonnet, D., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604453 · Cited by 162
Filella, X., & Giménez, N. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2012-0410 · Cited by 155
Associations of High-Grade Prostate Cancer withBRCA1andBRCA2Founder Mutations
Agalliu, I., Gern, R. W., Leanza, S. M., & Burk, R. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1822 · Cited by 147
Yamoah, K., Johnson, M. H., Choeurng, V., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.8912 · Cited by 144
Lazzeri, M., Haese, A., Abrate, A., TAILLE, A. D. L., Palou, J., McNicholas, T., Giovanni Lughezzani, A., Lista, G., Larcher, A., Bini, V., et al. (2013) · British Journal of Urology · doi:10.1111/bju.12217 · Cited by 112
Thorne, H., Willems, A. J., Niedermayr, E., Hoh, I., Li, J., Clouston, D. R., Mitchell, G., Fox, S. B., Hopper, J. L., & Bolton, D. M. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0397 · Cited by 111
Abdollah, F., Novara, G., Briganti, A., Scattoni, V., Raber, M., Roscigno, M., Suardi, N. R., Andrea Gallina, A., Artibani, W., Ficarra, V., et al. (2010) · Urology · doi:10.1016/j.urology.2010.08.048 · Cited by 102
Scattoni, V., Lazzeri, M., Lughezzani, G., et al. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.02.3184 · Cited by 99
Mahal, B. A., Aizer, A. A., Ziehr, D. R., Hyatt, A. S., Sammon, J. D., Schmid, M., Choueiri, T. K., Hu, J. C., Sweeney, C. J., Beard, C. J., et al. (2014) · Urology · doi:10.1016/j.urology.2014.05.009 · Cited by 96
Self-citationVickers, A. J., Gupta, A., Savage, C. J., Pettersson, K. S. I., Dahlin, A., Bjartell, A. S., Manjer, J., Scardino, P. T., Ulmert, D., & Lilja, H. G. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-1003 · Cited by 90
Self-citationThe effect of a single BRCA2 mutation on cancer in Iceland
Tulinius, H., Ólafsdóttir, G. H., Sigvaldason, H., Arason, A., Barkardottir, R. B., Egilsson, V., Ogmundsdottir, H. M., Tryggvadóttír, L., Gudlaugsdottir, S., & Eyfjord, J. E. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.7.457 · Cited by 89
Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era
Chen, Y., Page, J. H., Chen, R., & Giovannucci, E. L. (2008) · The Prostate · doi:10.1002/pros.20825 · Cited by 89
Age at Cancer Diagnosis for Blacks Compared With Whites in the United States
Robbins, H. A., Engels, E. A., Pfeiffer, R. M., & Shiels, M. S. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju489 · Cited by 74
Earlier age at diagnosis: Another dimension in cancer disparity?
Karami, S., Young, H. A., & Henson, D. E. (2007) · Cancer Detection and Prevention · doi:10.1016/j.cdp.2006.11.004 · Cited by 67
Boegemann, M., Stephan, C., Cammann, H., et al. (2015) · British Journal of Urology · doi:10.1111/bju.13139 · Cited by 66
MRI-targeted prostate biopsy: a review of technique and results
Robertson, N. L., Emberton, M., & Moore, C. M. (2013) · Nature Reviews Urology · doi:10.1038/nrurol.2013.196 · Cited by 52
Grill, S., Fallah, M., Leach, R. J., Thompson, I. M., Freedland, S. J., Hemminki, K., & Ankerst, D. P. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.09.018 · Cited by 33
Vickers, A. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.5547 · Cited by 12
Self-citation
Cited by
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments
Lone, S. N., Nisar, S., Masoodi, T., Singh, M., Rizwan, A., Hashem, S., El-Rifai, W., Bedognetti, D., Batra, S. K., Haris, M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01543-7 · Cited by 819
Analysis of DNA methylation in cancer: location revisited
Koch, A., Joosten, S. C., Feng, Z., de Ruijter, T. C., Draht, M. X., Melotte, V., Smits, K. M., Veeck, J., Herman, J. G., Van Neste, L., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0004-4 · Cited by 710
Drost, F.-J. H., Osses, D. F., Nieboer, D., Steyerberg, E. W., Bangma, C. H., Roobol, M. J., & Schoots, I. G. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012663.pub2 · Cited by 640
Fenton, J. J., Weyrich, M. S., Durbin, S., Liu, Y., Bang, H., & Melnikow, J. (2018) · JAMA · doi:10.1001/jama.2018.3712 · Cited by 555
Na, R., Zheng, S. L., Han, M., Yu, H., Jiang, D., Shah, S., Ewing, C. M., Zhang, L., Novakovic, K., Petkewicz, J., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.11.033 · Cited by 343
Metadata
- Authors
- Carroll, P. R., Parsons, J. K., Andriole, G., Bahnson, R. R., Castle, E. P., Catalona, W. J., Dahl, D. M., Davis, J. W., Epstein, J. I., Etzioni, R. B., Farrington, T., Hemstreet, G. P., Kawachi, M. H., Kim, S., Lange, P. H., Loughlin, K. R., Lowrance, W., Maroni, P., Mohler, J., Morgan, T. M., Moses, K. A., Nadler, R. B., Poch, M., Scales, C., Shaneyfelt, T. M., Smaldone, M. C., Sonn, G., Sprenkle, P., Vickers, A. J., Wake, R., Shead, D. A., & Freedman-Cass, D. A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2016-05
- Volume
- 14
- Issue
- 5
- Pages
- 509-519
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2393681916
- Cited by
- 342
- References
- 51
- FWCI
- 50.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.